MedTrace Logo

First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis

NCT03559166 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2020-03-19

No results posted yet for this study

Summary

First in Human single ascending dose followed by multiple ascending doses in healthy volunteers.

Conditions

Interventions

DRUG

BLD-2660

Randomized to active product or placebo

Sponsors & Collaborators

  • Blade Therapeutics

    lead INDUSTRY

Principal Investigators

  • Ben Snyder, MD · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-11
Primary Completion
2019-10-04
Completion
2019-10-04

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03559166 on ClinicalTrials.gov